Published in Cancer Weekly, June 10th, 2008
Under this agreement, Exiqon will use its miRCURY(TM) LNA(TM) products to discover microRNA biomarkers.
Specifically, the project focuses on identifying miRNA expression signatures associated with relapse and progression of breast cancer, and to develop and validate diagnostic tools that will guide patient management.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.